Business Context and Reporting Period
Cytosorbents Corporation (CTSO), a Delaware corporation, filed this Form 8-K on July 21, 2020, to report the entry into a material definitive agreement regarding an underwritten public offering of common stock.
Key Financial Metrics
This filing details a capital raise rather than operational performance metrics. Key figures include:
- Shares Issued: 5,263,158 Firm Shares of common stock.
- Offering Price: $9.50 per share.
- Gross Proceeds: Approximately $50.0 million (before underwriting discounts and expenses).
- Over-Allotment Option: Underwriters granted a 30-day option to purchase up to 789,473 additional shares.
- Expected Closing: On or about July 24, 2020.
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity as this is a transactional report, not a periodic financial statement.
Material Changes
The primary material change is the execution of an Underwriting Agreement with Cowen and Company LLC and SVB Leerink LLC to raise capital. This represents a significant increase in the company's equity base pending the closing of the transaction.
Guidance, Outlook, and Risks
The filing does not contain specific forward-looking guidance, management commentary on operations, or a discussion of risks beyond standard underwriting agreement terms. The transaction is subject to the satisfaction of customary closing conditions. The offering was registered under an existing shelf registration statement (File No. 333-226372).
Investor Verification Checklist
- Verify the final closing date and actual net proceeds after deducting underwriting discounts and commissions.
- Confirm whether the underwriters exercised the 30-day option to purchase the additional 789,473 shares.
- Review the full Underwriting Agreement (Exhibit 1.1) for specific indemnification obligations and termination provisions.
- Check subsequent filings for the use of proceeds and any impact on diluted earnings per share.